Early enteral feeding in postsurgical cancer patients. Fish oil structured lipid-based polymeric formula versus a standard polymeric formula
Kenler AS, Swails WS, Driscoll DF, DeMichele SJ, Daley B, Babineau TJ, Peterson MB, Bistrian BR
Annals of surgery · 85 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 1996-03-01 · Ann Surg · vol. 223 · número 3 · págs. 316–333
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 162 citas · más que el 100% de estudios similares · 17.8× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 39 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Clinical Nutrition and Gastroenterology · Enhanced Recovery After Surgery · Fatty Acid Research and Health
- Palabras clave
- early enteral nutrition, structured lipids, fish oil, medium-chain triglycerides, omega-3 fatty acids, eicosapentaenoic acid, upper gastrointestinal cancer, abdominal surgery, postoperative complications, infection control, urinary prostaglandins, liver function, renal function, nutritional support, jejunostomy
- MeSH
- humans, gastrointestinal neoplasms, carbohydrates, lipids, triglycerides, fish oils, caseins, enteral nutrition, postoperative care, nutrition assessment, prospective studies, double-blind method, time factors, adolescent, adult, aged, aged, 80 and over, middle aged, plant proteins, dietary
8 autores
- Andrew S. Kenler · autor de correspondencia
- Wendy S. Swails
- David F. Driscoll🇬🇧🇺🇸Abbott (United Kingdom); Abbott (United States)
- Stephen J. DeMichele🇺🇸Rutgers, The State University of New Jersey
- Brian James Daley🇺🇸Tufts Medical Center
- Timothy J. Babineau🇬🇧🇺🇸 · autor de correspondenciaAbbott (United Kingdom); Abbott (United States)
- Myron B. Peterson🇺🇸 · autor de correspondenciaTufts University
- Bruce Ryan Bistrian🇺🇸🇬🇧Harvard University; Abbott (United Kingdom); Abbott (United States)
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objectives
The authors compared the safety, gastrointestinal tolerance, and clinical efficacy of feeding an enteral diet containing a fish oil/medium-chain triglyceride structured lipid (FOSL-HN) versus an isonitrogenous, isocaloric formula (O-HN) in patients undergoing major abdominal surgery for upper gastrointestinal malignancies.
Summary background data
Previous studies suggest that feeding with n-3 fatty acids from fish oil can alter eicosanoid and cytokine production, yielding an improved immunocompetence and a reduced inflammatory response to injury. The use of n-3 fatty acids as a structured lipid can improve long-chain fatty acid absorption.
Methods
This prospective, blinded, randomized trial was conducted in 50 adult patients who were jejunally fed either FOSL-HN or O-HN for 7 days. Serum chemistries, hematology, urinalysis, gastrointestinal complications, liver and renal function, plasma and erythrocyte fatty acid analysis, urinary prostaglandins, and outcome parameters were measured at baseline and on day 7. Comparisons were made in 18 and 17 evaluable patients based a priori on the ability to reach a tube feeding rate of 40 mL/hour.
Results
Patients receiving FOSL-HN experienced no untoward side effects, significant incorporation of eicosapentaenoic acid into plasma and erythrocyte phospholipids, and a 50% decline in the total number of gastrointestinal complications and infections compared with patients given O-HN. The data strongly suggest improved liver and renal function during the postoperative period in the FOSL-HN group.
Conclusion
Early enteral feeding with FOSL-HN was safe and well tolerated. Results suggest that the use of such a formula during the postoperative period may reduce the number of infections and gastrointestinal complications per patient, as well as improve renal and liver function through modulation of urinary prostaglandin levels. Additional clinical trials to fully quantify clinical benefits and optimize nutritional support with FOSL-HN should be undertaken.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.